vs
FactSet（FDS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是FactSet的1.3倍（$772.1M vs $607.6M），FactSet净利率更高（25.1% vs 12.7%，领先12.4%），FactSet同比增速更快（6.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $90.4M），过去两年Revvity的营收复合增速更高（9.0% vs 5.5%）
FactSet是总部位于美国康涅狄格州诺沃克的金融数据与软件企业，为客户提供一体化数据及软件解决方案。2024财年，公司年度订阅价值与专业服务营收合计22亿美元，当前总市值约170亿美元。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FDS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$607.6M
营收增速更快
FDS
高出1.0%
5.9%
净利率更高
FDS
高出12.4%
12.7%
自由现金流更多
RVTY
多$71.4M
$90.4M
两年增速更快
RVTY
近两年复合增速
5.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $607.6M | $772.1M |
| 净利润 | $152.6M | $98.4M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 31.6% | 14.5% |
| 净利率 | 25.1% | 12.7% |
| 营收同比 | 6.9% | 5.9% |
| 净利润同比 | 1.7% | 3.9% |
| 每股收益（稀释后） | $4.06 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FDSRVTY
| Q4 25 | $607.6M | $772.1M | ||
| Q3 25 | $596.9M | $698.9M | ||
| Q2 25 | $585.5M | $720.3M | ||
| Q1 25 | $570.7M | $664.8M | ||
| Q4 24 | $568.7M | $729.4M | ||
| Q3 24 | $562.2M | $684.0M | ||
| Q2 24 | $552.7M | $691.7M | ||
| Q1 24 | $545.9M | $649.9M |
净利润FDSRVTY
| Q4 25 | $152.6M | $98.4M | ||
| Q3 25 | $153.6M | $46.7M | ||
| Q2 25 | $148.5M | $53.9M | ||
| Q1 25 | $144.9M | $42.2M | ||
| Q4 24 | $150.0M | $94.6M | ||
| Q3 24 | $89.5M | $94.4M | ||
| Q2 24 | $158.1M | $55.4M | ||
| Q1 24 | $140.9M | $26.0M |
毛利率FDSRVTY
| Q4 25 | 52.6% | — | ||
| Q3 25 | 51.6% | 53.6% | ||
| Q2 25 | 52.1% | 54.5% | ||
| Q1 25 | 52.8% | 56.5% | ||
| Q4 24 | 54.5% | — | ||
| Q3 24 | 54.1% | 56.3% | ||
| Q2 24 | 55.3% | 55.7% | ||
| Q1 24 | 53.3% | 54.6% |
营业利润率FDSRVTY
| Q4 25 | 31.6% | 14.5% | ||
| Q3 25 | 29.7% | 11.7% | ||
| Q2 25 | 33.2% | 12.6% | ||
| Q1 25 | 32.5% | 10.9% | ||
| Q4 24 | 33.6% | 16.3% | ||
| Q3 24 | 22.7% | 14.3% | ||
| Q2 24 | 36.6% | 12.4% | ||
| Q1 24 | 33.3% | 6.8% |
净利率FDSRVTY
| Q4 25 | 25.1% | 12.7% | ||
| Q3 25 | 25.7% | 6.7% | ||
| Q2 25 | 25.4% | 7.5% | ||
| Q1 25 | 25.4% | 6.4% | ||
| Q4 24 | 26.4% | 13.0% | ||
| Q3 24 | 15.9% | 13.8% | ||
| Q2 24 | 28.6% | 8.0% | ||
| Q1 24 | 25.8% | 4.0% |
每股收益（稀释后）FDSRVTY
| Q4 25 | $4.06 | $0.86 | ||
| Q3 25 | $4.03 | $0.40 | ||
| Q2 25 | $3.87 | $0.46 | ||
| Q1 25 | $3.76 | $0.35 | ||
| Q4 24 | $3.89 | $0.77 | ||
| Q3 24 | $2.33 | $0.77 | ||
| Q2 24 | $4.09 | $0.45 | ||
| Q1 24 | $3.65 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.7M | $919.9M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.2B | $7.3B |
| 总资产 | $4.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.63× | — |
8季度趋势，按日历期对齐
现金及短期投资FDSRVTY
| Q4 25 | $292.7M | $919.9M | ||
| Q3 25 | $355.1M | $931.4M | ||
| Q2 25 | $364.0M | $991.8M | ||
| Q1 25 | $287.0M | $1.1B | ||
| Q4 24 | $358.8M | $1.2B | ||
| Q3 24 | $492.6M | $1.2B | ||
| Q2 24 | $522.0M | $2.0B | ||
| Q1 24 | $450.2M | $1.7B |
总债务FDSRVTY
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.5B | — |
股东权益FDSRVTY
| Q4 25 | $2.2B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.2B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.0B | $7.7B | ||
| Q3 24 | $1.9B | $7.9B | ||
| Q2 24 | $1.9B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
总资产FDSRVTY
| Q4 25 | $4.2B | $12.2B | ||
| Q3 25 | $4.3B | $12.1B | ||
| Q2 25 | $4.3B | $12.4B | ||
| Q1 25 | $4.2B | $12.4B | ||
| Q4 24 | $4.0B | $12.4B | ||
| Q3 24 | $4.1B | $12.8B | ||
| Q2 24 | $4.0B | $13.4B | ||
| Q1 24 | $4.0B | $13.4B |
负债/权益比FDSRVTY
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $121.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $90.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 14.9% | 21.0% |
| 资本支出强度资本支出/营收 | 5.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.79× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $647.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FDSRVTY
| Q4 25 | $121.3M | $182.0M | ||
| Q3 25 | $212.1M | $138.5M | ||
| Q2 25 | $253.8M | $134.3M | ||
| Q1 25 | $174.0M | $128.2M | ||
| Q4 24 | $86.4M | $174.2M | ||
| Q3 24 | $163.2M | $147.9M | ||
| Q2 24 | $238.2M | $158.6M | ||
| Q1 24 | $143.8M | $147.6M |
自由现金流FDSRVTY
| Q4 25 | $90.4M | $161.8M | ||
| Q3 25 | $178.1M | $120.0M | ||
| Q2 25 | $228.6M | $115.5M | ||
| Q1 25 | $150.2M | $112.2M | ||
| Q4 24 | $60.5M | $149.8M | ||
| Q3 24 | $137.2M | $125.6M | ||
| Q2 24 | $216.9M | $136.6M | ||
| Q1 24 | $121.9M | $129.7M |
自由现金流率FDSRVTY
| Q4 25 | 14.9% | 21.0% | ||
| Q3 25 | 29.8% | 17.2% | ||
| Q2 25 | 39.0% | 16.0% | ||
| Q1 25 | 26.3% | 16.9% | ||
| Q4 24 | 10.6% | 20.5% | ||
| Q3 24 | 24.4% | 18.4% | ||
| Q2 24 | 39.2% | 19.7% | ||
| Q1 24 | 22.3% | 20.0% |
资本支出强度FDSRVTY
| Q4 25 | 5.1% | 2.6% | ||
| Q3 25 | 5.7% | 2.6% | ||
| Q2 25 | 4.3% | 2.6% | ||
| Q1 25 | 4.2% | 2.4% | ||
| Q4 24 | 4.5% | 3.4% | ||
| Q3 24 | 4.6% | 3.3% | ||
| Q2 24 | 3.9% | 3.2% | ||
| Q1 24 | 4.0% | 2.7% |
现金转化率FDSRVTY
| Q4 25 | 0.79× | 1.85× | ||
| Q3 25 | 1.38× | 2.97× | ||
| Q2 25 | 1.71× | 2.49× | ||
| Q1 25 | 1.20× | 3.03× | ||
| Q4 24 | 0.58× | 1.84× | ||
| Q3 24 | 1.82× | 1.57× | ||
| Q2 24 | 1.51× | 2.87× | ||
| Q1 24 | 1.02× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FDS
| Americas Segment | $399.7M | 66% |
| EMEA Segment | $149.1M | 25% |
| Asia Pacific Segment | $62.2M | 10% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
